Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo

Abstract

Chromosomal translocations affecting mixed lineage leukemia gene (MLL) result in acute leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is dependent on their interaction with menin, providing basis for therapeutic intervention. Here we report the development of highly potent and orally bioavailable small-molecule inhibitors of the menin-MLL interaction, MI-463 and MI-503, and show their profound effects in MLL leukemia cells and substantial survival benefit in mouse models of MLL leukemia. Finally, we demonstrate the efficacy of these compounds in primary samples derived from MLL leukemia patients. Overall, we demonstrate that pharmacologic inhibition of the menin-MLL interaction represents an effective treatment for MLL leukemias in vivo and provide advanced molecular scaffold for clinical lead identification.

Description

item.page.description.tableofcontents

item.page.relation.haspart

Cite As

Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., … Grembecka, J. (2015). Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell, 27(4), 589–602. http://doi.org/10.1016/j.ccell.2015.02.016

ISSN

1878-3686

Publisher

Series/Report

Sponsorship

Major

Extent

Identifier

Relation

Journal

Cancer Cell

Rights

Publisher Policy

Source

PMC

Alternative Title

Type

Article

Number

Volume

Conference Dates

Conference Host

Conference Location

Conference Name

Conference Panel

Conference Secretariat Location

Version

Author's manuscript

Full Text Available at

This item is under embargo {{howLong}}